Immuneering Advances Pancreatic Cancer Trial with First Patient Dosed in Phase 3 Study
Event summary
- First patient dosed in Phase 3 MAPKeeper 301 trial evaluating atebimetinib + mGnP in first-line pancreatic cancer.
- Trial compares atebimetinib + mGnP against standard GnP alone, with overall survival as the primary endpoint.
- Topline data readout anticipated in mid-2028.
- Atebimetinib is a novel MEK inhibitor designed for greater durability and tolerability.
- Global trial (NCT07562152) includes key secondary endpoints like progression-free survival and quality of life.
The big picture
Immuneering's Phase 3 trial represents a critical step in addressing the unmet need for effective first-line treatments in pancreatic cancer, a disease with a poor prognosis and limited therapeutic options. The trial's focus on overall survival and quality of life aligns with broader industry trends prioritizing patient-centric endpoints. Success in this trial could position Immuneering as a key player in the oncology space, particularly in MAPK pathway-driven cancers.
What we're watching
- Clinical Execution
- The pace at which Immuneering can enroll patients and meet trial milestones will determine the timeline for topline data.
- Regulatory Pathway
- Whether the Phase 3 data will support a regulatory filing for atebimetinib in pancreatic cancer.
- Competitive Landscape
- How Immuneering's approach compares to existing and emerging therapies for pancreatic cancer.